DNMT3A
DNA
As of the edition of 20 October 2026, DNMT3A (DNA, UniProt Q9Y6K1) has 2 drugs tested at it and 7 companies on the list, 0 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9Y6K1
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 47
- Disease areas
- Blood and lymph; Cancer; Immune system; Inherited and neonatal; Lungs and airways; Skin and connective tissue; Urinary and reproductive; Digestive system
- Registered trials of its drugs
- 1,072
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Azacitidine | Marketed | Phase 4 | Ends 2029 |
| Decitabine | Marketed | Phase 4 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 4 |
| Engaged | 2 |
| Undetermined | 1 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route B |
| Johnson & Johnson | Route B |
| Nippon Shinyaku | Route B |
The other 4 companies at DNMT3A
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at DNMT3A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.